Clinical Pharmacology & Biopharmaceutics
Open 91桃色
Our Group organises 3000+ Global Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open 91桃色 Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
Open 91桃色 Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers
Citations : 1089
Indexed In
- CAS Source Index (CASSI)
- Index Copernicus
- Google Scholar
- Sherpa Romeo
- Genamics JournalSeek
- RefSeek
- Hamdard University
- EBSCO A-Z
- OCLC- WorldCat
- Publons
- Euro Pub
- ICMJE
Useful Links
Recommended Journals
Related Subjects
Share This Page
BioMAP�?庐 human primary cell systems for improving drug discovery and development
Pharma Middle East
Nadia Tagnaouti
DiscoveRx Corporation Ltd., USA
Posters-Accepted Abstracts: Clin Pharmacol Biopharm
DOI:
Abstract
Improving the safety and effi cacy of drug candidates that enter clinical development require assays that are more predictive of human outcomes. The BioMAP platform uses human primary cells to model complex aspects of disease and tissue biology and can be applied to better understand biological mechanisms that underlie drug effi cacy and safety. Here we test Ibrutinib (PCI-32765), a Bruton芒�?�?s tyrosine kinase (BTK) inhibitor approved by the US FDA for B-cell malignancies, for biomarker activities in a broad range of human biology by profi ling in the Diversity PLUS芒�?垄 panel of 12 BioMAP systems and compare its activity profi le to that of a highly selective BTK inhibitor, GDC-0834, and other reference compounds in the BioMAP database.Biography
Nadia Tagnaouti has completed her PhD in Neuroscience at the age of 27 in Hamburg University, Germany. She has joined DiscoveRx, an innovative Drug Discovery provider, in 2008 and focused her activities in building the European Business as well as extending the company’s activities in Eastern Europe and the Middle East. While initial activities were mainly dealing with small molecules drug discovery, she has played an active role in broadening the usage of DiscoveRx Bioassays to Biologics and Biosimilars.
Email: NadiaT@discoverx.com
